Zilico Ltd’s cervical cancer diagnostic system ZedScan™ has been approved for use in Canada and Israel.
ZedScan has been awarded a class II medical device licence by Health Canada. The Health Canada licence means that the system, which includes Zilico’s patented Electrical Impedance Spectroscopy technology, has been approved for clinical use as an adjunct to colposcopy in Canada.
ZedScan has also now had its registration approved in Israel with AMAR, the Israeli Ministry of Health’s medical device regulation unit.
[ more details ]